RxDoctor Payments Data

Jessica Karp, DO

Urogynecology and Reconstructive Pelvic Surgery · Centerville, OHNPI 1023243698

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.9%), travel and lodging and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Axonics, Inc. at 45.3% of the total. Reporting peaked in 2024 at $3,772 and has fallen 92.3% since, to $289 in 2025.

$5,668in general payments, 2019–2025

Across 80 payments — averaging $70.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$3K
  • Intuitive Surgical$2K
  • Medtronic$560
  • Coloplast$245
  • Astellas Pharma US Inc$202
  • Boston Scientific$151
  • plus $355 from 8 others

What the payments were for

  • Travel & lodging$1,86333%
  • Food & beverage$2,26040%
  • Education$1,54527%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,668 in reported general payments places this provider in the 65th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.

See all urogynecology and reconstructive pelvic surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$118,443
Medicare patients
142
Services billed
1,819

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron60$44,818
MyrbetriqMirabegron62$35,385
Estradiol130$6,965
Methenamine Hippurate24$2,193
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst94$959
Clobetasol Propionate15$449
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet16$308
Cephalexin148$301
Fluconazole24$113
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav21$99
Ciprofloxacin Hcl23$86
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$67
Ibuprofen18$51
Levofloxacin14$49
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$202$35,38562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.

Other urogynecology and reconstructive pelvic surgery in Centerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →